MedPath
HSA Approval

FRUZAQLA CAPSULE 5MG

SIN17113P

FRUZAQLA CAPSULE 5MG

FRUZAQLA CAPSULE 5MG

October 17, 2024

TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantTAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

CAPSULE

ORAL

Medical Information

L01EK04

Manufacturer Information

TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE. LTD.

STA Pharmaceutical Switzerland SA

Active Ingredients

Fruquintinib

5mg

Fruquintinib

Documents

Package Inserts

Fruzaqla Capsule PI.pdf

Approved: October 17, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

FRUZAQLA CAPSULE 5MG - HSA Approval | MedPath